A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts without systematic methodology or primary human data.
PubMed 37000372 · doi:10.1007/s11154-023-09800-w
What was done
This narrative review synthesized literature on the role of CXC chemokines and chemokine receptors in low-grade systemic inflammation associated with obesity, type 2 diabetes (T2D), and nonalcoholic fatty liver disease (NAFLD). The authors examined the immunomodulatory mechanisms, migratory functions, and predictive potential of CXC chemokine profiling.
What was found
The abstract reports no numerical data or effect sizes. It presents conceptual relationships, noting that CXC chemokines govern leukocyte and macrophage recruitment in inflamed adipose tissue, and hypothesizes that CXC chemokine profiling could predict therapeutic targets for obesity-related metabolic diseases.
Why it matters
Clarifying how specific CXC chemokines drive obesity-induced inflammation could help identify novel biomarkers or therapeutic strategies for metabolic complications like insulin resistance, T2D, and NAFLD.
Limits
As a narrative review, it presents mechanistic hypotheses rather than primary empirical data. No systematic search protocol, study selection criteria, sample sizes, or quantitative outcome measures are provided in the abstract.
Cited by
- supports Individuals with obesity have higher circulating levels of pro-inflammatory cytokines and chemokines.